Elanco Animal Health (NYSE: ELAN) — Company Overview, News & Financial Data
Elanco Animal Health delivers innovative products for companion and livestock animals, focusing on disease prevention and overall well-being.
Elanco Animal Health
Elanco Animal Health is a global animal health company that develops, manufactures, and markets products for pets and livestock. Headquartered in Greenfield, Indiana, the company operates across two principal segments: Pet Health and Farm Animal. Its product portfolio includes parasiticides, pain and dermatology therapeutics, vaccines, nutritional health additives, and disease prevention products for dogs, cats, cattle, poultry, swine, and aquaculture. The company serves veterinarians, livestock producers, and pet owners through commercial operations across North America, Europe, Latin America, and the Asia-Pacific region, utilizing a global network of research and development facilities and manufacturing sites.
Snapshot
Operations
Products and/or services of Elanco Animal Health
- Companion Animal Parasiticides: External and internal parasite control products including collar treatments, topical solutions, and oral chewables for dogs and cats that prevent flea, tick, heartworm, and intestinal worm infestations across global veterinary and retail distribution channels.
- Companion Animal Therapeutics: Prescription pharmaceuticals for dogs and cats targeting canine osteoarthritis pain, surgical inflammation, canine dermatology, and chronic conditions, distributed through licensed veterinary clinics and specialist practices across North America, Europe, and international markets.
- Cattle Health Solutions: Feed additives, pharmaceuticals, and biological vaccines for beef and dairy cattle that enhance feed conversion efficiency, prevent enteric and respiratory diseases, and reduce livestock enteric methane emissions across commercial livestock operations globally.
- Poultry Disease Control: Vaccines, coccidiostats, nutritional health products, and antimicrobial treatments formulated for commercial broiler, layer, and turkey production systems to prevent systemic avian infections and maintain flock intestinal health across global agricultural facilities.
- Swine Health Products: Vaccines, feed-administered medications, and targeted therapeutics for commercial pork production facilities, engineered to prevent swine respiratory disease, porcine reproductive issues, and gastrointestinal bacterial infections across global pork supply chains.
- Aquaculture Health Management: Specialized biological vaccines, water-administered treatments, and parasiticides developed for commercial aquaculture operations to protect farmed salmon, trout, and other aquatic species against sea lice infestations and bacterial infections in marine farming operations.
Elanco Animal Health executive team
- Jeffrey N. SimmonsPresident, CEO & Director
- Robert M. VanHimbergenExecutive VP & CFO
- Ramiro Martin CabralExecutive VP & President of Elanco International
- Ellen de BrabanderExecutive Vice President of Research, Development & Regulatory Affairs
- Timothy J. BettingtonExecutive Vice President of Center of Strategic Growth
- James M. MeerSenior VP & Chief Accounting Officer
- David S. KinardExecutive Vice President of Human Resources, Corporate Communications & Administration
- Tiffany Ann KanagaVP of Investor Relations & ESG
- Shiv O'NeillExecutive Vice President, General Counsel & Corporate Secretary
- Larbi Van LierSenior Vice President of Asia
Latest news about Elanco Animal Health
Key financials
Reported results for Elanco Animal Health, in USD.
- Market cap
- 12B
- Revenue (TTM)
- 5B
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- -4.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 4.7B | 252M | -232M | |
| 4.4B | 251M | 338M | |
| 4.4B | 326M | -1.2B | |
| 4.4B | 384M | -78M |